Literature DB >> 10022441

A mouse monoclonal antibody to a thyrotropin receptor ectodomain variant provides insight into the exquisite antigenic conformational requirement, epitopes and in vivo concentration of human autoantibodies.

G D Chazenbalk1, Y Wang, J Guo, J S Hutchison, D Segal, J C Jaume, S M McLachlan, B Rapoport.   

Abstract

We used the secreted TSH receptor (TSHR) ectodomain variant TSHR-289 (truncated at amino acid residue 289 with a 6-histidine tail) to investigate properties of TSHR autoantibodies in Graves' disease. Sequential concanavalin A and Ni-chelate chromatography extracted milligram quantities of TSHR-289 (approximately 20-40% purity) from the culture medium. Nanogram quantities of this material neutralized the TSH binding inhibitory activity in all 15 Graves' sera studied. We generated a mouse monoclonal antibody (mAb), 3BD10, to partially purified TSHR-289. Screening of a TSHR complementary DNA fragment expression library localized the 3BD10 epitope to 27 amino acids at the N-terminus of the TSHR, a cysteine-rich segment predicted to be highly conformational. 3BD10 preferentially recognized native, as opposed to reduced and denatured, TSHR-289, but did not interact with the TSH holoreceptor on the cell surface. Moreover, mAb 3BD10 could extract from culture medium TSHR-289 nonreactive with autoantibodies, but not the lesser amount (approximately 25%) of TSHR-289 molecules capable of neutralizing autoantibodies. Although the active form of TSHR-289 in culture medium was stable at ambient temperature, stability was reduced at 37 C, explaining the mixture of active and inactive molecules in medium harvested from cell cultures. In conclusion, studies involving a TSHR ectodomain variant indicate the exquisite conformational requirements of TSHR autoantibodies. Even under "native" conditions, only a minority of molecules in highly potent TSHR-289 preparations neutralize patients' autoantibodies. Therefore, Graves' disease is likely to be caused by even lower concentrations of autoantibodies than previously thought. Finally, reciprocally exclusive binding to TSHR-289 by human autoantibodies and a mouse mAb with a defined epitope suggests that the extreme N-terminus of the TSHR is important for autoantibody recognition.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10022441     DOI: 10.1210/jcem.84.2.5481

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  24 in total

1.  Cytokines, IgG subclasses and costimulation in a mouse model of thyroid autoimmunity induced by injection of fibroblasts co-expressing MHC class II and thyroid autoantigens.

Authors:  X M Yan; J Guo; P Pichurin; K Tanaka; J C Jaume; B Rapoport; S M McLachlan
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

2.  Insight into thyroid-stimulating autoantibody interaction with the thyrotropin receptor N-terminus based on mutagenesis and re-evaluation of ambiguity in this region of the receptor crystal structure.

Authors:  Sepehr Hamidi; Chun-Rong Chen; Sandra M McLachlan; Basil Rapoport
Journal:  Thyroid       Date:  2011-08-11       Impact factor: 6.568

3.  Studies in mice deficient for the autoimmune regulator (Aire) and transgenic for the thyrotropin receptor reveal a role for Aire in tolerance for thyroid autoantigens.

Authors:  Alexander V Misharin; Yuji Nagayama; Holly A Aliesky; Basil Rapoport; Sandra M McLachlan
Journal:  Endocrinology       Date:  2009-03-05       Impact factor: 4.736

4.  Nanoparticles Bearing TSH Receptor Protein and a Tolerogenic Molecule Do Not Induce Immune Tolerance but Exacerbate Thyroid Autoimmunity in hTSHR/NOD.H2h4 Mice.

Authors:  Sandra M McLachlan; Holly A Aliesky; Basil Rapoport
Journal:  J Immunol       Date:  2019-04-03       Impact factor: 5.422

5.  A unique mouse strain that develops spontaneous, iodine-accelerated, pathogenic antibodies to the human thyrotrophin receptor.

Authors:  Basil Rapoport; Holly A Aliesky; Bianca Banuelos; Chun-Rong Chen; Sandra M McLachlan
Journal:  J Immunol       Date:  2015-03-30       Impact factor: 5.422

6.  High-level intrathymic thyrotrophin receptor expression in thyroiditis-prone mice protects against the spontaneous generation of pathogenic thyrotrophin receptor autoantibodies.

Authors:  S M McLachlan; H A Aliesky; B Banuelos; S Lesage; R Collin; B Rapoport
Journal:  Clin Exp Immunol       Date:  2017-02-20       Impact factor: 4.330

7.  Thyroid-stimulating autoantibodies in Graves disease preferentially recognize the free A subunit, not the thyrotropin holoreceptor.

Authors:  Gregorio D Chazenbalk; Pavel Pichurin; Chun-Rong Chen; Francesco Latrofa; Alan P Johnstone; Sandra M McLachlan; Basil Rapoport
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

8.  Role of the transgenic human thyrotropin receptor A-subunit in thyroiditis induced by A-subunit immunization and regulatory T cell depletion.

Authors:  Y Mizutori; Y Nagayama; D Flower; A Misharin; H A Aliesky; B Rapoport; S M McLachlan
Journal:  Clin Exp Immunol       Date:  2008-09-22       Impact factor: 4.330

9.  Shared and unique susceptibility genes in a mouse model of Graves' disease determined in BXH and CXB recombinant inbred mice.

Authors:  Sandra M McLachlan; Holly A Aliesky; Pavel N Pichurin; Chun-Rong Chen; Robert W Williams; Basil Rapoport
Journal:  Endocrinology       Date:  2007-12-27       Impact factor: 4.736

10.  Attenuation of induced hyperthyroidism in mice by pretreatment with thyrotropin receptor protein: deviation of thyroid-stimulating to nonfunctional antibodies.

Authors:  Alexander V Misharin; Yuji Nagayama; Holly A Aliesky; Yumiko Mizutori; Basil Rapoport; Sandra M McLachlan
Journal:  Endocrinology       Date:  2009-04-23       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.